Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and <scp>CSF</scp> Cell Composition
The differential CSF composition associated with sVCAM-1 serum level changes suggests that selective immune cell trafficking may occur during aGAP, potentially contributing to PML prevention.
Authors
- Tilman Schneider‐Hohendorf (ORCID: https://orcid.org/0000-0002-3717-5176)
- John E. Anderson (ORCID: https://orcid.org/0000-0002-3741-4843)
- Julie Czerkowicz
- Regina Berkovich (ORCID: https://orcid.org/0000-0001-7637-0241)
- Susan Goelz
- Nicholas Schwab (ORCID: https://orcid.org/0000-0001-5494-9885)
- Marie Deffner
- Eric Baetscher (ORCID: https://orcid.org/0000-0003-1532-1328)
- Evan L. Riddle
- Emily Katsnelson
- Janine Ferrant-Orgettas
Institutions
- Biogen (United States) (US)
- Oregon Health & Science University (US)
- University Hospital Münster (DE)
- Oncotherapeutics (United States) (US)
- Advanced Imaging Research (United States) (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1002/acn3.70207
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biogen